OrthoPediatrics Corp. Named One the 2025 Best Places to Work in Indiana
OrthoPediatrics President & CEO David Bailey commented, 'I'm so proud of our organization for being named one of the 'Best Places to Work' in Indiana for a 9th time. Our leadership team is committed to fostering an engaging and inclusive culture, and meaningful career experiences for all our associates. We are always investing in our people and looking for new and attractive ways to build on what we have created at OrthoPediatrics. It's an honor to know our colleagues feel proud to work for our company and advance our cause of helping KIDS.'
The list features honorees from all corners of the state and more than 20 industries. In this 20th edition of the Indiana Chamber of Commerce initiative, a total of 150 companies made the cut.
'We all recognize that currently there is intense competition for talent. This program is a great way for organizations to take the temperature of their culture and how it's resonating with today's workers,' says Indiana Chamber President and CEO Vanessa Green Sinders. 'Companies on the right cultural track also are much more likely to be effective across the board and have increased productivity and overall success. We salute each of this year's winners for their commitment to displaying best practices in their workplaces, which are enabling them to attract and retain employees.'
This statewide survey and awards program is designed to identify, recognize, and honor the participating employers in Indiana with the leading workplace cultures. The final rankings will be announced at an awards ceremony on Wednesday, April 30th, 2025, and then published in the Indiana Chamber's BizVoice® magazine after the event. For more information on the Best Places to Work in Indiana program, visit: www.bestplacestoworkindiana.com.
About OrthoPediatrics Corp.Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such, it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 75 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics' global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com. For more information about the OrthoPediatrics Specialty Bracing portfolio, please visit www.opsb.com.
Investor ContactPhilip Trip TaylorGilmartin Groupphilip@gilmartinir.com415-937-5406Sign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Is Bitcoin About to Enter the S&P 500? MicroStrategy Now Qualifies For Inclusion, Analyst Says
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Anyone invested in the S&P 500 may soon own Bitcoin indirectly. MicroStrategy (NASDAQ:MSTR) maxi Jeff Walton said Tuesday on X that the company had cleared the final hurdle to qualify for the highly coveted index, which could make Bitcoin an index asset by proxy. Since MicroStrategy's inclusion in the Nasdaq 100, the big question has been whether the company with the most significant Bitcoin holdings of any public firm can get included in the S&P 500 next. But one hurdle stood in its way for months: net profitability over 12 months. Don't Miss: — no wallets, just price speculation and free paper trading to practice different strategies. Grow your IRA or 401(k) with Crypto – . Under previous accounting rules, MicroStrategy was forced to report its Bitcoin holdings at an impaired price, leading to negative earnings on unrealized losses. However, following a Financial Accounting Standards Board rule change allowing firms to record their digital assets at fair value, MicroStrategy has finally been able to clear the profitability criteria. With Bitcoin closing at around $107,000 on Monday, Walton said MicroStrategy will report an estimated $14 billion profit in Q2, translating to an estimated $11 billion net profit over the past 12 months. "This clears the FINAL criteria Strategy needed to be considered for the S&P 500," he said. But qualifying may not be enough for inclusion. After qualifying, the S&P 500 committee still has complete discretion over which companies get included. This process is likely to be "controversial and heavily debated," according to Walton. Trending: New to crypto? on Coinbase. The committee typically considers index balance, economic representation and stability before making its decision. Analysts are divided on whether MicroStrategy's Bitcoin accumulation model will be an issue for the committee, as some argue that the firm now largely operates like a closed-ended fund. "S&P excludes ETFs and closed-end funds from its index because they want the index to contain operating businesses, not investment funds," Brooklyn Investment Group equities chief Antii Petajisto told Bloomberg last year, discussing MicroStrategy's odds of being included in the index. Whatever the case, market watchers will have to wait until the third week of September to know if the firm will be included, as the second quarter inclusion window has the firm makes the cut, it would become the second cryptocurrency-related company to do so this year after Coinbase (NASDAQ:COIN) in May. 'Inclusion in the S&P 500 means every major index fund holds Strategy shares—further cementing Bitcoin's mainstream legitimacy,' Bitcoin content creator 'Alexes Nakamoto' said. MicroStrategy stock is trading at $396 pre-market with a market capitalization of $113 billion. At last look, it also holds 597,325 BTC worth nearly $64 billion, representing nearly 3% of the entire asset supply. Read Next: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — Image: Shutterstock This article Is Bitcoin About to Enter the S&P 500? MicroStrategy Now Qualifies For Inclusion, Analyst Says originally appeared on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Investors in OptimizeRx (NASDAQ:OPRX) have unfortunately lost 55% over the last three years
It is doubtless a positive to see that the OptimizeRx Corporation (NASDAQ:OPRX) share price has gained some 73% in the last three months. But that is small recompense for the exasperating returns over three years. Indeed, the share price is down a tragic 55% in the last three years. Some might say the recent bounce is to be expected after such a bad drop. While many would remain nervous, there could be further gains if the business can put its best foot forward. It's worthwhile assessing if the company's economics have been moving in lockstep with these underwhelming shareholder returns, or if there is some disparity between the two. So let's do just that. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Because OptimizeRx made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size. Over three years, OptimizeRx grew revenue at 16% per year. That's a fairly respectable growth rate. So some shareholders would be frustrated with the compound loss of 16% per year. The market must have had really high expectations to be disappointed with this progress. So this is one stock that might be worth investigating further, or even adding to your watchlist. The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail). We consider it positive that insiders have made significant purchases in the last year. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. So we recommend checking out this free report showing consensus forecasts It's good to see that OptimizeRx has rewarded shareholders with a total shareholder return of 34% in the last twelve months. Notably the five-year annualised TSR loss of 1.3% per year compares very unfavourably with the recent share price performance. The long term loss makes us cautious, but the short term TSR gain certainly hints at a brighter future. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Take risks, for example - OptimizeRx has 1 warning sign we think you should be aware of. If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
2 hours ago
- Yahoo
Calculating The Intrinsic Value Of InterDigital, Inc. (NASDAQ:IDCC)
InterDigital's estimated fair value is US$251 based on 2 Stage Free Cash Flow to Equity InterDigital's US$225 share price indicates it is trading at similar levels as its fair value estimate Analyst price target for IDCC is US$220 which is 12% below our fair value estimate Today we will run through one way of estimating the intrinsic value of InterDigital, Inc. (NASDAQ:IDCC) by taking the expected future cash flows and discounting them to their present value. Our analysis will employ the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward. Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. To begin with, we have to get estimates of the next ten years of cash flows. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years. A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars: 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 Levered FCF ($, Millions) US$214.2m US$274.2m US$307.8m US$336.9m US$362.2m US$384.4m US$404.3m US$422.5m US$439.6m US$455.9m Growth Rate Estimate Source Analyst x3 Analyst x1 Est @ 12.26% Est @ 9.46% Est @ 7.51% Est @ 6.14% Est @ 5.18% Est @ 4.51% Est @ 4.04% Est @ 3.71% Present Value ($, Millions) Discounted @ 8.1% US$198 US$235 US$244 US$247 US$246 US$241 US$235 US$227 US$219 US$210 ("Est" = FCF growth rate estimated by Simply Wall St)Present Value of 10-year Cash Flow (PVCF) = US$2.3b We now need to calculate the Terminal Value, which accounts for all the future cash flows after this ten year period. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.9%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 8.1%. Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = US$456m× (1 + 2.9%) ÷ (8.1%– 2.9%) = US$9.2b Present Value of Terminal Value (PVTV)= TV / (1 + r)10= US$9.2b÷ ( 1 + 8.1%)10= US$4.2b The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is US$6.5b. In the final step we divide the equity value by the number of shares outstanding. Relative to the current share price of US$225, the company appears about fair value at a 11% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind. The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at InterDigital as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 8.1%, which is based on a levered beta of 1.184. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business. See our latest analysis for InterDigital Strength Earnings growth over the past year exceeded the industry. Debt is not viewed as a risk. Dividends are covered by earnings and cash flows. Weakness Dividend is low compared to the top 25% of dividend payers in the Software market. Opportunity Good value based on P/E ratio and estimated fair value. Threat Annual earnings are forecast to decline for the next 3 years. Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. The DCF model is not a perfect stock valuation tool. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" If a company grows at a different rate, or if its cost of equity or risk free rate changes sharply, the output can look very different. For InterDigital, we've compiled three fundamental aspects you should further research: Risks: For instance, we've identified 2 warning signs for InterDigital that you should be aware of. Future Earnings: How does IDCC's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing! PS. Simply Wall St updates its DCF calculation for every American stock every day, so if you want to find the intrinsic value of any other stock just search here. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $359.72 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
